

Jörg Wissel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/592602/publications.pdf>

Version: 2024-02-01

35
papers

2,182
citations

430874

18
h-index

395702

33
g-index

41
all docs

41
docs citations

41
times ranked

1852
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment, goal setting, and botulinum neurotoxin a therapy in the management of post-stroke spastic movement disorder: updated perspectives on best practice. Expert Review of Neurotherapeutics, 2022, 22, 27-42.	2.8	14
2	Module 2. The Journal of the International Society of Physical and Rehabilitation Medicine, 2022, 5, S23-S37.	0.3	1
3	Early clinical predictors of post stroke spasticity. Topics in Stroke Rehabilitation, 2021, 28, 508-518.	1.9	14
4	Efficacy of incobotulinumtoxinA for the treatment of adult lower-limb post-stroke spasticity, including pes equinovarus. Annals of Physical and Rehabilitation Medicine, 2021, 64, 101376.	2.3	9
5	A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: An international group consensus. Journal of Rehabilitation Medicine, 2021, 53, jrm00134.	1.1	26
6	Post-Stroke Spasticity. , 2021, , 149-173.		5
7	Early brain imaging predictors of post-stroke spasticity. Journal of Rehabilitation Medicine, 2021, 53, jrm00169.	1.1	7
8	Ergonomic Recommendations in Ultrasound-Guided Botulinum Neurotoxin Chemodenervation for Spasticity: An International Expert Group Opinion. Toxins, 2021, 13, 249.	3.4	6
9	Botulinum Toxin Services for Neurorehabilitation: Recommendations for Challenges and Opportunities during the COVID-19 Pandemic. Toxins, 2021, 13, 584.	3.4	1
10	European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A. Journal of Rehabilitation Medicine, 2021, .	1.1	4
11	Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis. Toxins, 2021, 13, 887.	3.4	7
12	Goal analysis in patients with limb spasticity treated with incobotulinumtoxinA in the TOWER study. Disability and Rehabilitation, 2020, , 1-7.	1.8	5
13	Effectiveness of AbobotulinumtoxinA in Post-stroke Upper Limb Spasticity in Relation to Timing of Treatment. Frontiers in Neurology, 2020, 11, 104.	2.4	19
14	Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA. Health and Quality of Life Outcomes, 2020, 18, 51.	2.4	11
15	Post hoc analysis of shoulder spasticity and safety following treatment with incobotulinumtoxinA. Journal of Rehabilitation Medicine, 2020, 52, jrm00028.	1.1	6
16	What clinicians and patients want: The past, the presence, and the future of the botulinum toxins. Toxicon, 2020, 177, 46-51.	1.6	4
17	The role of physical and rehabilitation medicine in the COVID-19 pandemic: The clinician's view. Annals of Physical and Rehabilitation Medicine, 2020, 63, 554-556.	2.3	112
18	COVID-19 pandemic. What should Physical and Rehabilitation Medicine specialists do? A clinician's perspective. European Journal of Physical and Rehabilitation Medicine, 2020, 56, 515-524.	2.2	87

#	ARTICLE	IF	CITATIONS
19	Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity – Insights from recent studies. <i>Toxicon</i> , 2018, 147, 100-106.	1.6	25
20	Pathophysiology of Spasticity and Therapeutic Approach. <i>Biosystems and Biorobotics</i> , 2018, , 449-469.	0.3	1
21	Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 642-650.	1.9	30
22	Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. <i>Stroke</i> , 2018, 49, 2129-2137.	2.0	26
23	A comprehensive person-centered approach to adult spastic paresis: a consensus-based framework. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2018, 54, 605-617.	2.2	38
24	Identifying unmet needs in long-term stroke care using in-depth assessment and the Post-Stroke Checklist – The Managing Aftercare for Stroke (MAS-I) study. <i>European Stroke Journal</i> , 2018, 3, 237-245.	5.5	51
25	Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity. <i>Neurology</i> , 2017, 88, 1321-1328.	1.1	99
26	Validity and Reliability of the Spasticity-Associated Arm Pain Scale. <i>Journal of Pain Management & Medicine</i> , 2017, 03, .	0.2	5
27	OnabotulinumtoxinA Improves Pain in Patients With Post-Stroke Spasticity: Findings From a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 17-26.	1.2	42
28	Post-stroke Spasticity: Predictors of Early Development and Considerations for Therapeutic Intervention. <i>PM and R</i> , 2015, 7, 60-67.	1.6	73
29	Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians). <i>Journal of Medical Economics</i> , 2014, 17, 618-625.	2.1	48
30	Pathophysiology of spasticity in stroke. <i>Neurology</i> , 2013, 80, S20-6.	1.1	139
31	Toward an epidemiology of poststroke spasticity. <i>Neurology</i> , 2013, 80, S13-9.	1.1	245
32	Early development of spasticity following stroke: a prospective, observational trial. <i>Journal of Neurology</i> , 2010, 257, 1067-1072.	3.6	240
33	Occurrence and Clinical Predictors of Spasticity After Ischemic Stroke. <i>Stroke</i> , 2010, 41, 2016-2020.	2.0	315
34	European consensus table on the use of botulinum toxin type A in adult spasticity. <i>Journal of Rehabilitation Medicine</i> , 2009, 41, 13-25.	1.1	282
35	Management of Spasticity Associated Pain with Botulinum Toxin A. <i>Journal of Pain and Symptom Management</i> , 2000, 20, 44-49.	1.2	184